Epidarex Capital

Epidarex Capital is a transatlantic venture firm that invests in early-stage, high-growth life science companies in under-ventured markets. The firm focuses on providing risk capital and expertise to create, support and build young companies, including spinouts, from leading research institutions in both established and emerging life science hubs. Epidarex invests in early-stage life science opportunities, particularly in biotechnology, pharmaceuticals, medical devices, and health technology, typically providing seed or Series A funding to spin out innovations from leading medical research universities and institutions. Their investment strategy emphasizes transformative technologies that address significant unmet medical needs, focusing on major disease areas including oncology, cardiometabolic, autoimmune and neurological conditions. The firm leverages its deep scientific and industry networks to identify transformative life science investments, building companies from scratch to create value and shared success.